+86 400-600-8315
bd@biogenous.cn
Unit 01-02 & 09-12, 8th Floor, Building 22, No. 388 Xinping Street, Suzhou Industrial Park, Suzhou Area, Jiangsu Pilot Free Trade Zone, China
Fields:
Applicable to High-Throughput New Drug R&D of Patient-Derived Organoid Libraries
Keypoints:
High-throughput organoid modeling, quality control, identification, high content confocal imaging and analysis system, drug efficiency screening, validation, etc.
Service Process:
Screening of 100+ drugs using 3 patient-derived organoids, screening of 6-8 effective tumor growth inhibition candidates, and then validation of these drug candidates using 14 other patient-derived organoids.
Advancements:
1) High-throughput organoid culture and compatibility with high-throughput automated testing equipment;
2) Standardized platforms and methods to improve the reproducibility and stability of results;
3) Organoid drug screening technology reaches the level of leading international laboratories.
Cell Stem Cell, in revision
Applicable to clinical oncology research, antitumor drug development workers, non-clinical preclinical new drug evaluation, small molecule drugs, tumor immunotherapy drug efficacy screening, etc.
Related Fields:
CAR-T immunotherapy, tumor microenvironment, oncolytic virus, antibody drug, targeted drug, small molecule drug
Service Hotline
bd@biogenous.cn
support@biogenous.cn
order@biogenous.cn
info@biogenous.cn